Evaluating regional workshops on strengthening the capacity of healthcare professional associations to achieve Millennium Development Goals 4 and 5.

OBJECTIVE: In 2007-2008, the Partnership for Maternal, Newborn and Child Health (PMNCH), Geneva, organized capacity-building workshops in Malawi, Burkina Faso, and Bangladesh. Their aim was to strengthen the role of healthcare professional associations (HCPAs) in national reproductive, maternal, newborn, and child health (RMNCH) planning and programs. The present cross-sectional study evaluated the outcomes of these regional workshops. METHODS: In 2010, a structured survey, telephone interviews of workshop participants, and a document review were used to analyze the impact of these workshops. RESULTS: Overall, HCPAs in only 2 of the 17 participating countries (11.8%) were able to increase their impact on RMNCH planning. Although all countries developed action plans, 15 (88.2%) were unable to fully implement them despite increased interactions among HCPAs and with the Ministry of Health (MOH). Nine countries (52.9%) implemented their action plans partly. Engagement of the MOH emerged as a strong indicator of HCPA contribution toward RMNCH planning. CONCLUSION: Strong and sustained follow-up by PMNCH, a clear sense of ownership by HCPAs, designated staff, and financial resources emerged as important determinants for the implementation of action plans. These workshops were generally successful in both encouraging HCPA collaboration and marching toward Millennium Development Goals 4 and 5

Estimating Benzathine Penicillin Need for the Treatment of Pregnant Women Diagnosed with Syphilis during Antenatal Care in High-Morbidity Countries.

BACKGROUND:Congenital syphilis continues to be a preventable cause of global stillbirth and neonatal morbidity and mortality. Shortages of injectable penicillin, the only recommended treatment for pregnant women and infants with syphilis, have been reported by high-morbidity countries. We sought to estimate current and projected annual needs for benzathine penicillin in antenatal care settings for 30 high morbidity countries that account for approximately 33% of the global burden of congenital syphilis. METHODS:Proportions of antenatal care attendance, syphilis screening coverage in pregnancy, syphilis prevalence among pregnant women, and adverse pregnancy outcomes due to untreated maternal syphilis reported to WHO were applied to 2012 birth estimates for 30 high syphilis burden countries to estimate current and projected benzathine penicillin need for prevention of congenital syphilis. RESULTS:Using current antenatal care syphilis screening coverage and seroprevalence, we estimated the total number of women requiring treatment with at least one injection of 2.4 MU of benzathine penicillin in these 30 countries to be 351,016. Syphilis screening coverage at or above 95% for all 30 countries would increase the number of women requiring treatment with benzathine penicillin to 712,030. Based on WHO management guidelines, 351,016 doses of weight-based benzathine penicillin would also be needed for the live-born infants of mothers who test positive and are treated for syphilis in pregnancy. Assuming availability of penicillin and provision of treatment for all mothers diagnosed with syphilis, an estimated 95,938 adverse birth outcomes overall would be prevented including 37,822 stillbirths, 15,814 neonatal deaths, and 34,088 other congenital syphilis cases. CONCLUSION:Penicillin need for maternal and infant syphilis treatment is high among this group of syphilis burdened countries. Initiatives to ensure a stable and adequate supply of benzathine penicillin for treatment of maternal syphilis are important for congenital syphilis prevention, and will be increasingly critical in the future as more countries move toward elimination targets

Estimates of syphilis-associated adverse birth outcomes and estimates of those averted through maternal treatment with benzathine penicillin in 30 high-morbidity countries.

<p>Estimates of syphilis-associated adverse birth outcomes and estimates of those averted through maternal treatment with benzathine penicillin in 30 high-morbidity countries.</p

Estimated paediatric benzathine penicillin regimens needed for treatment of infants exposed to syphilis during pregnancy in 30 high-morbidity countries.

<p>Estimated paediatric benzathine penicillin regimens needed for treatment of infants exposed to syphilis during pregnancy in 30 high-morbidity countries.</p

Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews

<div><p>Background</p><p>Benzathine penicillin G (BPG) is the only recommended treatment to prevent mother-to-child transmission of syphilis. Due to recent reports of country-level shortages of BPG, an evaluation was undertaken to quantify countries that have experienced shortages in the past 2 years and to describe factors contributing to these shortages.</p><p>Methods and findings</p><p>Country-level data about BPG shortages were collected using 3 survey approaches. First, a survey designed by the WHO Department of Reproductive Health and Research was distributed to 41 countries and territories in the Americas and 41 more in Africa. Second, WHO conducted an email survey of 28 US Centers for Disease Control and Prevention country directors. An additional 13 countries were in contact with WHO for related congenital syphilis prevention activities and also reported on BPG shortages. Third, the Clinton Health Access Initiative (CHAI) collected data from 14 countries (where it has active operations) to understand the extent of stock-outs, in-country purchasing, usage behavior, and breadth of available purchasing options to identify stock-outs worldwide. CHAI also conducted in-person interviews in the same 14 countries to understand the extent of stock-outs, in-country purchasing and usage behavior, and available purchasing options. CHAI also completed a desk review of 10 additional high-income countries, which were also included. BPG shortages were attributable to shortfalls in supply, demand, and procurement in the countries assessed. This assessment should not be considered globally representative as countries not surveyed may also have experienced BPG shortages. Country contacts may not have been aware of BPG shortages when surveyed or may have underreported medication substitutions due to desirability bias. Funding for the purchase of BPG by countries was not evaluated. In all, 114 countries and territories were approached to provide information on BPG shortages occurring during 2014–2016. Of unique countries and territories, 95 (83%) responded or had information evaluable from public records. Of these 95 countries and territories, 39 (41%) reported a BPG shortage, and 56 (59%) reported no BPG shortage; 10 (12%) countries with and without BPG shortages reported use of antibiotic alternatives to BPG for treatment of maternal syphilis. Market exits, inflexible production cycles, and minimum order quantities affect BPG supply. On the demand side, inaccurate forecasts and sole sourcing lead to under-procurement. Clinicians may also incorrectly prescribe BPG substitutes due to misperceptions of quality or of the likelihood of adverse outcomes.</p><p>Conclusions</p><p>Targets for improvement include drug forecasting and procurement, and addressing provider reluctance to use BPG. Opportunities to improve global supply, demand, and use of BPG should be prioritized alongside congenital syphilis elimination efforts.</p></div

Clinic-based evaluation study of the diagnostic accuracy of a dual rapid test for the screening of HIV and syphilis in pregnant women in Nigeria

<div><p>Background</p><p>Screening pregnant women for HIV and syphilis is recommended by WHO in order to reduce mother-to-child transmission. We evaluated the field performance, feasibility, and acceptability of a dual rapid diagnostic test (RDT) for HIV and syphilis test in antenatal clinic settings in Nigeria.</p><p>Methods and findings</p><p>Participants were recruited at 12 antenatal clinic sites in three states of Nigeria. All consenting individuals were tested according to the national HIV testing algorithm, as well as a dual RDT, the SD BIOLINE HIV/Syphilis Duo Test (Alere, USA), in the clinic. To determine sensitivity, specificity and concordance, whole blood samples were obtained for repeat RDT performance in the laboratory, as well as reference tests for HIV and syphilis. Dual test acceptability and operational characteristics were assessed among participants and clinic staff.</p><p>The prevalence of HIV among the 4,551 enrollees was 3.0% (138/4551) using the national clinic-based HIV testing algorithm. Positive and negative percent agreement of the HIV component of the dual RDT were 100.0% (95% CI 99.7–100.0) and 99.9% (95% CI 99.7–100.0) respectively, when compared with the national rapid testing algorithm. The prevalence of syphilis, using TPHA as the reference test, was low at 0.09% (4/4550). The sensitivity of the syphilis component of the dual RDT could not be calculated as no positive results were observed for patients that were positive for syphilis by TPHA. Each of the only four TPHA-positive specimens had RPR titers of 1:1 (neat), indicative of non-active syphilis. The specificity of the syphilis component of the dual RDT was 99.9% (95% CI 99.8–100.0).</p><p>The dual RDT received favorable feasibility ratings among antenatal care clinic staff. Acceptability among study participants was high with most women reporting preference for rapid dual HIV/syphilis testing.</p><p>Conclusions</p><p>The SD BIOLINE HIV/Syphilis Duo Test showed a high overall diagnostic accuracy for HIV and a high specificity for syphilis diagnosis in antenatal clinic settings. This study adds to a growing body of evidence that supports the clinic-based use of dual tests for HIV and syphilis among pregnant women.</p></div

Identified drivers of BPG stock-outs across the value chain.

<p>*API, active pharmaceutical ingredient; BPG, benzathine penicillin G; FDF, final dose formulator; GMP, Good Manufacturing Practice.</p

Select responses from providers describing barriers to administration of BPG.

<p>Select responses from providers describing barriers to administration of BPG.</p

Countries with reported shortages of benzathine penicillin G (BPG) during 2014–2016.

<p>Countries with reported shortages of benzathine penicillin G (BPG) during 2014–2016.</p